US: FDA says no to psychedelic MDMA as PTSD treatment

Medical company Lykos Therapeutics on Friday said the US Food and Drug Administration (FDA) had rejected its bid for approval to use the psychedelic substance MDMA to treat post-traumatic stress disorder (PTSD). 

Lykos said it had received a formal “complete response letter” to its application refusing it, at least for the time being. 

“The FDA communicated that it had completed its review of the [new drug application] and determined that it could not be approved based on data submitted…